Candidate Pool Clause Samples

The Candidate Pool clause defines the group of individuals who are eligible for consideration for a particular position or opportunity within an organization or process. Typically, this clause outlines the criteria for inclusion in the pool, such as qualifications, experience, or other relevant attributes, and may specify how candidates are identified or nominated. By clearly establishing who is in the candidate pool, this clause ensures transparency and fairness in the selection process, helping to prevent disputes and misunderstandings about eligibility.
Candidate Pool. When Human Resources is unable to fill one of these positions through the voluntary transfer process in Article 18, it is agreed that, after conferring with the Union, the position may be filled from the candidate pool.
View SourceView Similar (5)
Candidate Pool. In order to create a pool of prospective qualified candidates, general postings for tentative principal and vice principal vacancies will occur on or before March 31st annually. Additional postings for these positions may occur throughout the school year based on the needs of the system and as determined by the Superintendent. Candidates screened during the first posting will remain in the applicant pool until a general posting is done the following March.
View Source
Candidate Pool. Immediately following receipt of a notice from Atlantic requesting Isis to commence the work (such notice to be given within [***] of the grant of Regulatory Approval in the USA of an Alicaforsen Product for the treatment of pouchitis, but in no event will such notice be given later than [***] after the Effective Date), Isis agrees to, at its sole cost and expense, commence in vitro screening in accordance with a written work plan to be mutually agreed upon by both Parties (the “Work Plan”), to attempt to discover between [***] and [***] Second Generation ICAM-1 ASO Drug Candidates (the “Candidate Pool”) (the “Second Generation ICAM-1 Research Program”). Isis agrees to use Commercially Reasonable Efforts and the Quality Standard when discharging any of its obligations under the Work Plan and will keep or cause to be kept written laboratory notebooks and other records and reports of its progress with the Work Plan and its activities under the Work Plan in sufficient detail and in a good scientific manner for all purposes including patent purposes. Isis will report its progress with the Second Generation ICAM-1 Research Program to the JDC.
View Source

Related to Candidate Pool

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Human Leukocyte Antigen Testing This plan covers human leukocyte antigen testing for A, B, and DR antigens once per member per lifetime to establish a member’s bone marrow transplantation donor suitability in accordance with R.I. General Law §27-20-36. The testing must be performed in a facility that is: • accredited by the American Association of Blood Banks or its successors; and • licensed under the Clinical Laboratory Improvement Act as it may be amended from time to time. At the time of testing, the person being tested must complete and sign an informed consent form that also authorizes the results of the test to be used for participation in the National Marrow Donor program.

  • Candidates The Superintendent or designee shall invite all current candidates for the office of Board member to attend: